Genzyme, Alcon Deals Throw Spotlight on Earn-Outs, Now Commonplace in Private Deals
Executive Summary
Should Genzyme Corp. succumb to the advances of Sanofi-Aventis, contingent value rights (CVRs, or earn-out payments) will likely play a significant part in bridging the valuation gap that now exists between those companies.